Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

200 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro.
Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA. Fisher JE, et al. Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):133-8. doi: 10.1073/pnas.96.1.133. Proc Natl Acad Sci U S A. 1999. PMID: 9874784 Free PMC article.
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Lipfert L, Fisher JE, Wei N, Scafonas A, Su Q, Yudkovitz J, Chen F, Warrier S, Birzin ET, Kim S, Chen HY, Tan Q, Schmidt A, Dininno F, Rohrer SP, Hammond ML, Rodan GA, Freedman LP, Reszka AA. Lipfert L, et al. Among authors: fisher je. Mol Endocrinol. 2006 Mar;20(3):516-33. doi: 10.1210/me.2005-0190. Epub 2005 Oct 13. Mol Endocrinol. 2006. PMID: 16223974
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist.
Duggan ME, Duong LT, Fisher JE, Hamill TG, Hoffman WF, Huff JR, Ihle NC, Leu CT, Nagy RM, Perkins JJ, Rodan SB, Wesolowski G, Whitman DB, Zartman AE, Rodan GA, Hartman GD. Duggan ME, et al. Among authors: fisher je. J Med Chem. 2000 Oct 5;43(20):3736-45. doi: 10.1021/jm000133v. J Med Chem. 2000. PMID: 11020288
Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis.
Hutchinson JH, Halczenko W, Brashear KM, Breslin MJ, Coleman PJ, Duong LT, Fernandez-Metzler C, Gentile MA, Fisher JE, Hartman GD, Huff JR, Kimmel DB, Leu CT, Meissner RS, Merkle K, Nagy R, Pennypacker B, Perkins JJ, Prueksaritanont T, Rodan GA, Varga SL, Wesolowski GA, Zartman AE, Rodan SB, Duggan ME. Hutchinson JH, et al. Among authors: fisher je. J Med Chem. 2003 Oct 23;46(22):4790-8. doi: 10.1021/jm030306r. J Med Chem. 2003. PMID: 14561098
200 results